Last Updated : February 21, 2020
Today, CADTH has issued final recommendations for:
tafamidis (Vyndaqel)
Indications: transthyretin-mediated amyloidosis
Recommendation: Reimburse with clinical criteria and/or conditions
Last Updated : February 21, 2020